Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
Megadott ok: IRB did not approve
A legfontosabb adatok
- Fázis
- 1. fázis
A vizsgálat adatai
- Ki végzi
- Methodist Health System
- Azonosító
- NCT06222437
- A regiszteradat frissítve
- 2026. március 23.
- Eredeti leírás
The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.A teljes eredeti leírásKevesebb
The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.
Bevonási feltételek: Age 18-45; Body mass index(BMI) > 30; Diagnosis of PCOS; Normal thyroid stimulating hormone, prolactin, follicle-stimulating hormone (FSH), estradiol, and normal progesterone.
Kizáró feltételek: Medications excluded: any hormone-containing contraceptive - oral contraceptive pills, Progesterone-only pill, depo-provera, oral provera, progesterone-containing intrauterine contraceptive device; Letrozole, clomiphene citrate, FSH therapy; 5α reductase inhibitors; Androgen receptor blockers; Insulin; Hysterectomy; Endometrial ablation.